Recurrent or Metastatic Head and Neck Cancer Pipeline: Comprehensive Insights and Emerging Therapies

DelveInsight's report, "Recurrent or Metastatic Head and Neck Cancer Pipeline Insight 2025", provides a comprehensive analysis of the pipeline landscape for this devastating disease. As of August 2025, 40+ companies and 40+ pipeline drugs are actively being developed to treat recurrent or metastatic head and neck cancer. The report highlights promising therapies, including those from Eisai Co Ltd, Sinocelltech, Merck, and Sichuan Baili Pharmaceutical.

Key Takeaways:

• On 19 August 2025, Bicara Therapeutics announced a study to evaluate the safety and efficacy of ficerafusp alfa in combination with pembrolizumab versus placebo with pembrolizumab in 1L PD-L1-positive, recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC).
• Exelixis conducted a Phase 2/3 trial of zanzalintinib in combination with pembrolizumab versus zanzalintinib-matched placebo in combination with pembrolizumab in subjects with programmed death-ligand 1 (PD-L1) positive recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) incurable by local therapies who have not received prior systemic therapy for recurrent or metastatic disease.
• The leading companies in the Recurrent or Metastatic Head and Neck Cancer pipeline include Eisai Co Ltd, Sinocelltech, Merck, Nanobiotix, Sichuan Baili Pharmaceutical, Adlai Nortye Biopharma, BioNTech, PDS Biotechnology, Shanghai Miracogen, Incyte Corporation, Checkmate Pharmaceuticals, NATCO Pharma, Agenus, Jiangsu Hengrui Medicine, and Cue Biopharma.
• Promising Therapies in this space include docetaxel (XRP6976), cisplatin, 5-fluorouracil (5-FU), Pemetrexed, Cetuximab, Carboplatin, and others.
• EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies are covered in the report.

Statistics:

• 40+ companies are working to develop 40+ pipeline therapies for Recurrent or Metastatic Head and Neck Cancer treatment.
• On 19 August 2025, Bicara Therapeutics announced a study to evaluate the safety and efficacy of ficerafusp alfa in combination with pembrolizumab versus placebo with pembrolizumab in 1L PD-L1-positive, recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC).
• Exelixis conducted a Phase 2/3 trial of zanzalintinib in combination with pembrolizumab versus zanzalintinib-matched placebo in combination with pembrolizumab in subjects with programmed death-ligand 1 (PD-L1) positive recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) incurable by local therapies who have not received prior systemic therapy for recurrent or metastatic disease.

Sources:

M2 PRESSWIRE-August 26, 2025-: Recurrent or Metastatic Head and Neck cancer Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies (C)1994-2025 M2 COMMUNICATIONS RDATE:25082025

DelveInsight's, "Recurrent or Metastatic Head and Neck cancer Pipeline Insight 2025" report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Recurrent or Metastatic Head and Neck cancer pipeline landscape.